Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
ACE Convergence Acquisition Corp is a shell companies business based in the US. ACE Convergence Acquisition shares (ACEVU) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||$10.38|
|52-week range||$9.92 - $15.00|
|50-day moving average||$10.20|
|200-day moving average||$10.60|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||0.19%|
|1 month (2021-09-22)||1.82%|
|3 months (2021-07-22)||2.77%|
|6 months (2021-04-22)||-3.61%|
|1 year (2020-10-22)||3.80%|
|2 years (2019-10-18)||N/A|
|3 years (2018-10-18)||N/A|
|5 years (2016-10-18)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||0%|
|Return on equity TTM||-9999999%|
|Market capitalisation||$286.4 million|
TTM: trailing 12 months
There are currently 79 ACE Convergence Acquisition shares held short by investors – that's known as ACE Convergence Acquisition's "short interest". This figure is 0% down from 79 last month.
There are a few different ways that this level of interest in shorting ACE Convergence Acquisition shares can be evaluated.
ACE Convergence Acquisition's "short interest ratio" (SIR) is the quantity of ACE Convergence Acquisition shares currently shorted divided by the average quantity of ACE Convergence Acquisition shares traded daily (recently around 292.59259259259). ACE Convergence Acquisition's SIR currently stands at 0.27. In other words for every 100,000 ACE Convergence Acquisition shares traded daily on the market, roughly 270 shares are currently held short.
However ACE Convergence Acquisition's short interest can also be evaluated against the total number of ACE Convergence Acquisition shares, or, against the total number of tradable ACE Convergence Acquisition shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ACE Convergence Acquisition's short interest could be expressed as 0% of the outstanding shares (for every 100,000 ACE Convergence Acquisition shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable ACE Convergence Acquisition shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ACE Convergence Acquisition.
Find out more about how you can short ACE Convergence Acquisition stock.
We're not expecting ACE Convergence Acquisition to pay a dividend over the next 12 months.
ACE Convergence Acquisition Corp. does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Wilmington, Delaware. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.